secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001140361-25-023265
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics gets up to $2M non-dilutive funding from RD Fund for MERTK gene therapy program
--------------------------------------------------------------------------------

- Up to $2 million non-dilutive funding from RD Fund (Foundation Fighting Blindness) for OPGx-MERTK preclinical program.
- OPGx-MERTK targets retinitis pigmentosa caused by MERTK gene mutations; no approved therapies exist.
- Funding expected to support IND-enabling studies and advance gene therapy pipeline for inherited retinal diseases.
- Cash runway extended into second half of fiscal year 2026, based on current projections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125023265/0001140361-25-023265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125023265/ef20050882_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-023265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer